Encouraging Results With Vaccine Against Pancreatic Cancer Developed at CINJ

'Encouraging' Period of Stable Disease Suggested in Direct Injection Vaccine Treatment of Pancreatic Cancer. Research from Rutgers Cancer Institute of New Jersey to be presented at the Pancreatic Cancer-focused meeting held by AACR in New Orleans.
Published Online: May 21, 2014
Research from Rutgers Cancer Institute of New Jersey shows that the ‘first in man’ series of vaccine injections given directly into a pancreatic cancer tumor is not only well tolerated,  but also suggests an “encouraging” period of stable disease.  Results from a Phase I clinical trial conducted at the Cancer Institute of New Jersey are being given as part of a poster presentation at the American Association for Cancer Research (AACR) Pancreatic Cancer: Innovations in Research and Treatment conference being held in New Orleans this week.

Vaccine therapies are designed to strengthen the body’s immune defenses and are typically given in the arm or leg. In a previous study, investigators at the Cancer Institute showed that using a vaccine treatment for bladder and breast cancer tumors in laboratory models resulted in a reversal of the traditional immune blockade, as well as the development of tumor specific immunity throughout the body. This tumor specific immunity showed the potential of blocking the growth of the original tumor as well as eliminating small tumor deposits that can cause the cancer to spread.  Building on this research, investigators further tested this vaccine in a direct injection method in patients who were not candidates for surgery to remove their cancer. The Cancer Institute’s Associate Director for Education and Training Edmund Lattime, PhD, who is also a professor of surgery at Rutgers Robert Wood Johnson Medical School, and Elizabeth Poplin, MD, co-director of the Cancer Institute’s Gastrointestinal/Hepatobiliary Program and a professor of medicine at Robert Wood Johnson Medical School are the lead investigators of the study.  

Press release: 

Source: Rutgers

Recommended Articles
Although the cost of oral oncolytic medications can vary greatly, cost sharing routinely plays less of a role because patients with cancer nearly always reach their maximum out-of-pocket limits, especially in late-stage disease care. Bruce A. Feinberg, DO, and Brian B. Kiss, MD, recently addressed this issue in the final segment on palliative care from the Oncology Stakeholders Summit, Spring 2015 meeting.
In the sixth entry of our Insights discussion on palliative care from the Oncology Stakeholders Summit, Spring 2015 meeting, Bruce A. Feinberg, DO, and Brian B. Kiss, MD, address the decision-making process regarding whether a patient receives oral or infusion medications during end-of-life care.
Patient-reported outcomes are beginning to influence FDA approvals and coverage decision making by payers. How oral oncolytics are affecting quality of life and patient preferences was also discussed in this fifth segment of the Oncology Stakeholders Summit, Spring 2015 series, with Bruce A. Feinberg, DO, and Brian B. Kiss, MD.
This week the Supreme Court ruled in favor of the government in King v. Burwell, preserving access to healthcare subsidies for millions of Americans, and the high cost of cancer drug was in the spotlight.